RxDoctor Payments DataLook up a doctor →

Joseph Ayoub, MD

Cardiovascular Disease · Council Bluffs, IANPI 1902888365

Payments from drug & device makers

$19,309in general payments, 2019–2025

Across 393 payments — averaging $49.13 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Medtronic$14K
  • E.r. Squibb & Sons, L.L.C.$624
  • Abbott$592
  • Novartis$528
  • Johnson & Johnson$476
  • Amgen$415
  • plus $3K from 32 others

What the payments were for

  • Travel & lodging$6,96636%
  • Food & beverage$12,33364%
  • Education$100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$19,309 in reported general payments places this provider in the 85th percentile of 142 cardiovascular disease providers in Iowa.

See all cardiovascular disease providers in Iowa

Medicare billing

Part B allowed, 2024
$447,673
Medicare patients
1,863
Services billed
8,647

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban1,243$842,528
XareltoRivaroxaban267$249,353
EntrestoSacubitril/Valsartan162$137,061
Repatha SureclickEvolocumab82$66,906
MultaqDronedarone Hcl29$38,697
VascepaIcosapent Ethyl46$26,372
Praluent PenAlirocumab32$16,516
JardianceEmpagliflozin16$11,744
OzempicSemaglutide11$10,480
Ranolazine ErRanolazine92$9,935
CorlanorIvabradine Hcl15$9,200
Amiodarone Hcl888$7,762
Icosapent Ethyl16$6,086
Metoprolol Succinate801$6,003
Atorvastatin Calcium808$5,168

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis$298$842,5281,243 claims
Johnson & JohnsonXarelto$476$249,353267 claims
NovartisEntresto$528$137,061162 claims
Sanofi-aventis U.S. LLCMultaq$87$38,69729 claims
Boehringer IngelheimJardiance$36$11,74416 claims
Novo NordiskOzempic$15$10,48011 claims
AmgenCorlanor$415$9,20015 claims
AstraZenecaBrilinta$251$4,58511 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 142 cardiovascular disease providers in Iowa.

Other cardiovascular disease in Council Bluffs

See the full list for Iowa

Where these figures come from

Is this you, or does something look wrong? →